Evidence obtained from anova to reason cross-species infection and cross-subtype mutation in neuraminidases of influenza A viruses

Transboundary and Emerging Diseases

Volumn 57, Issue 4, 2010, Pages 254-261

  Yan, S ^a   Wu, G ^b  

^a NATIONAL ENGINEERING RESEARCH CENTER FOR NON FOOD BIOREFINERY   (China)

^b DreamSciTech Consulting   (China)

Author keywords

Amino acid pair; Influenza A virus; Inter and intra ; Model I and model II anova; neuraminidase; Species; Subtype; Variation

Indexed keywords

SIALIDASE;

ANALYSIS OF VARIANCE; ANIMAL; ANIMAL DISEASE; ARTICLE; CLASSIFICATION; ENZYMOLOGY; GENETIC VARIABILITY; GENETICS; HUMAN; INFLUENZA; INFLUENZA VIRUS A; ORTHOMYXOVIRUS INFECTION; PANDEMIC; SPECIES DIFFERENCE; VIROLOGY; ZOONOSIS;

ANALYSIS OF VARIANCE; ANIMALS; GENETIC VARIATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; SPECIES SPECIFICITY; ZOONOSES;

AVES; INFLUENZA A VIRUS; INFLUENZAVIRUS A;

EID: 77958143789     PISSN: 18651674     EISSN: 18651682     Source Type: Journal    
DOI: 10.1111/j.1865-1682.2010.01143.x     Document Type: Article

References (74)

1. Althaus, I. W., J. J. Chou, A. J. Gonzales, M. R. Diebel, K. C. Chou, F. J. Kezdy, D. L. Romero, P. A. Aristoff, W. G. Tarpley, and F. Reusser, 1993: Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J. Biol. Chem. 268, 6119-6124.
2. Basler, C. F., 2007: Influenza viruses: basic biology and potential drug targets. Infect. Disord. Drug Targets. 7, 282-293.
3. Cheng, X., M. Eisenbraun, Q. Xu, H. Zhou, D. Kulkarni, K. Subbarao, G. Kemble, and H. Jin, 2009: H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines. PLoS ONE 4, e4436.
4. Chou, K. C., 1987: The biological functions of low-frequency phonons: 6. A possible dynamic mechanism of allosteric transition in antibody molecules. Biopolymers. 26, 285-295.
5. Chou, K. C., 1988: Review: low-frequency collective motion in biomacromolecules and its biological functions. Biophys. Chem. 30, 3-48.
6. Chou, K. C., 1989: Graphical rules in steady and non-steady enzyme kinetics. J. Biol. Chem. 264, 12074-12079.
7. Chou, K. C., 1990: Review: applications of graph theory to enzyme kinetics and protein folding kinetics. Steady and non-steady state systems. Biophys. Chem. 35, 1-24.
8. Chou, K. C., 1993: A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. J. Biol. Chem. 268, 16938-16948.
9. Chou, K. C., 1996: Review: prediction of HIV protease cleavage sites in proteins. Anal. Biochem. 233, 1-14.
10. Chou, K. C., 2001: Prediction of protein cellular attributes using pseudo amino acid composition. Proteins Struct. Func. Genet. (Erratum: ibid., 2001, Vol.44, 60), 43, 246-255.
11. Chou, K. C., 2004: Review: structural bioinformatics and its impact to biomedical science. Curr. Med. Chem. 11, 2105-2134.
12. Chou, K. C., 2005: Prediction of G-protein-coupled receptor classes. J. Proteome Res. 4, 1413-1418.
13. Chou, K. C., Shen. H.B. 2009: Review: recent advances in developing web-servers for predicting protein attributes. Nat. Sci. 2, 63-92. (openly accessible at ).
14. Chou, K. C., and H. B. Shen, 2007a: Signal-CF: a subsite-coupled and window-fusing approach for predicting signal peptides. Biochem. Biophys. Res. Commun. 357, 633-640.
15. Chou, K. C., and H. B. Shen, 2007b: Review: recent progresses in protein subcellular location prediction. Anal. Biochem. 370, 1-16.
16. Chou, K. C., and H. B. Shen, 2007c: MemType-2L: a Web server for predicting membrane proteins and their types by incorporating evolution information through Pse-PSSM. Biochem. Biophys. Res. Commun. 360, 339-345.
17. Chou, K. C., and H. B. Shen, 2008: ProtIdent: a web server for identifying proteases and their types by fusing functional domain and sequential evolution information. Biochem. Biophys. Res. Commun. 376, 321-325.
18. Chou, K. C., and H. B. Shen, 2010: A new method for predicting the subcellular localization of eukaryotic proteins with both single and multiple sites: euk-mPLoc 2.0. PLoS ONE 5, e9931.
19. Chou, K. C., and G. P. Zhou, 1982: Role of the protein outside active site on the diffusion-controlled reaction of enzyme. J. Am. Chem. Soc. 104, 1409-1413.
20. Chou, K. C., F. J. Kezdy, and F. Reusser, 1994: Review: steady-state inhibition kinetics of processive nucleic acid polymerases and nucleases. Anal. Biochem. 221, 217-230.
21. De Clercq, E., 2006: Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 12, 1015-1025.
22. Crusat, M., and M. D. De Jong, 2007: Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir. Ther. 12, 593-602.
23. Du, Q. S., S. Q. Wang, and K. C. Chou, 2007: Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem. Biophys. Res. Commun. 362, 525-531.
24. Du, Q. S., R. B. Huang, C. H. Wang, X. M. Li, and K. C. Chou, 2009: Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus. J. Theor. Biol. 259, 159-164.
25. Du, Q. S., R. B. Huang, S. Q. Wang, and K. C. Chou, 2010: Designing inhibitors of M2 proton channel against H1N1 swine influenza virus. PLoS ONE 5, e9388.
26. Ferraris, O., and B. Lina, 2008: Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 41, 13-19.
27. Furuse, Y., A. Suzuki, T. Kamigaki, and H. Oshitani, 2009: Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis. Virol. J. 6, 67-79.
28. Globig, A., C. Staubach, M. Beer, U. Köppen, W. Fiedler, M. Nieburg, H. Wilking, E. Starick, J. P. Teifke, O. Werner, F. Unger, C. Grund, C. Wolf, H. Roost, F. Feldhusen, F. J. Conraths, T. C. Mettenleiter, and T. C. Harder, 2009: Epidemiological and ornithological aspects of outbreaks of highly pathogenic avian influenza virus H5N1 of Asian lineage in wild birds in Germany, 2006 and 2007. Transbound. Emerg. Dis. 56, 57-72.
29. Gong, K., L. Li, J. F. Wang, F. Cheng, D. Q. Wei, and K. C. Chou, 2009: Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design. Med. Chem. 5, 242-249.
30. Grebe, K. M., J. W. Yewdell, and J. R. Bennink, 2008: Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10, 1024-1029.
31. Huang, R. B., Q. S. Du, C. H. Wang, and K. C. Chou, 2008: An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochem. Biophys. Res. Commun. 377, 1243-1247.
32. Influenza virus resources., 2010: .
33. Von Itzstein, M., and R. Thomson, 2009: Anti-influenza drugs: the development of sialidase inhibitors. Handb. Exp. Pharmacol. 189, 111-154.
34. Khanna, M., P. Kumar, K. Choudhary, B. Kumar, and V. K. Vijayan, 2008: Emerging influenza virus: a global threat. J. Biosci. 33, 475-482.
35. Kuiken, T., and J. K. Taubenberger, 2008: Pathology of human influenza revisited. Vaccine 26(Suppl 4), D59-D66.
36. Lackenby, A., C. I. Thompson, and J. Democratis, 2008: The potential impact of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis. 21, 626-638.
37. Leroux-Roels, I., and G. Leroux-Roels, 2009: Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev. Vaccines 8, 401-423.
38. Lin, W. Z. X. Xiao, and K. C. Chou, 2009: GPCR-GIA: a web-server for identifying G-protein coupled receptors and their families with grey incidence analysis. Protein Eng. Des. Sel. 22, 699-705.
39. Liu, Y., J. Zhang, and W. Xu, 2007: Recent progress in rational drug design of neuraminidase inhibitors. Curr. Med. Chem. 14, 2872-2891.
40. Ma, W., R. E. Kahn, and J. A. Richt, 2008: The pig as a mixing vessel for influenza viruses: human and veterinary implications. J. Mol. Genet. Med. 3, 158-166.
41. Michaelis, M., H. W. Doerr, and J. Cinatl Jr, 2009: Of chickens and men: avian influenza in humans. Curr. Mol. Med. 9, 131-151.
42. Palache, B., and R. Krause, 2009: Progress with human H5N1 vaccines: a perspective from industry. Expert Rev. Vaccines 8, 391-400.
43. Pan, C., G. Wang, M. Liao, G. H. Zhang, and S. Jiang, 2009: High genetic and antigenic similarity between a swine H3N2 influenza A virus and a prior human influenza vaccine virus: a possible immune pressure-driven cross-species transmission. Biochem. Biophys. Res. Commun. 385, 402-407.
44. Pappaioanou, M., 2009: Highly pathogenic H5N1 avian influenza virus: cause of the next pandemic? Comp. Immunol. Microbiol. Infect. Dis. 32, 287-300.
45. Pielak, R. M., and J. J. Chou, 2010: Flu channel drug resistance: a tale of two sites. Protein and Cell 1, 246-258.
46. Pielak, R. M., R. Schnell, and J. J. Chou, 2009: Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc. Natl. Acad. Sci. U S A 106, 7379-7384.
47. Qi, X., X. Li, P. Rider, W. Fan, H. Gu, L. Xu, Y. Yang, S. Lu, H. Wang, and F. Liu, 2009: Molecular characterization of highly pathogenic H5N1 avian influenza A viruses isolated from raccoon dogs in China. PLoS ONE 4, e4682.
48. Qi, J. P., Y. S. Ding, S. H. Shao, X. H. Zeng, and K. C. Chou, 2010: Cellular responding kinetics based on a model of gene regulatory networks under radiotherapy. Health 2, 137-146.
49. Sandrock, C., and T. Kelly, 2007: Clinical review: update of avian influenza A infections in humans. Crit. Care 11, 209.
50. Scalera, N. M., and S. B. Mossad, 2009: The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus. Postgrad. Med. 121, 43-47.
51. Schnell, J. R., and J. J. Chou, 2008: Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451, 591-595.
52. Skeik, N., and F. I. Jabr, 2008: Influenza viruses and the evolution of avian influenza virus H5N1. Int. J. Infect. Dis. 12, 233-238.
53. Sokal, R. R., and F. J. Rohlf, 1995: Biometry: The Principles and Practices of Statistics in Biological Research, 3rd edn. W. H. Freeman, New York. pp. 203-217.
54. Spackman, E., 2008: A brief introduction to the avian influenza virus. Methods Mol. Biol. 436, 1-6.
55. Sullivan, S. J., R. M. Jacobson, W. R. Dowdle, and G. A. Poland, 2010: 2009 H1N1 influenza. Mayo Clin. Proc. 85, 64-76.
56. Swayne, D. E., and D. Kapczynski, 2008: Strategies and challenges for eliciting immunity against avian influenza virus in birds. Immunol. Rev. 225, 314-331.
57. Thacker, E., and B. Janke, 2008: Swine influenza virus: zoonotic potential and vaccination strategies for the control of avian and swine influenzas. J. Infect. Dis. 197(Suppl 1), S19-S24.
58. Vajo, Z., 2009: Influenza A (H5N1) pandemic prototype vaccine Fluval. Expert Rev Vaccines 8, 619-624.
59. Wang, S. Q., Q. S. Du, and K. C. Chou, 2007: Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem. Biophys. Res. Commun. 354, 634-640.
60. Wang, J., R. M. Pielak, M. A. McClintock, and J. J. Chou, 2009a: Solution structure and functional analysis of the influenza B proton channel. Nat. Struct. Mol. Biol. 16, 1267-1271.
61. Wang, S. Q., Q. S. Du, R. B. Huang, D. W. Zhang, and K. C. Chou, 2009b: Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Biochem. Biophys. Res. Commun. 386, 432-436.
62. Wei, D. Q., Q. S. Du, H. Sun, and K. C. Chou, 2006: Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem. Biophys. Res. Commun. 344, 1048-1055.
63. Wei, H., C. H. Wang, Q. S. Du, J. Meng, and K. C. Chou, 2009: Investigation into adamantane-based M2 inhibitors with FB-QSAR. Med. Chem. 5, 305-317.
64. Wu, G., and S. Yan, 2002: Randomness in the primary structure of protein: methods and implications. Mol. Biol. Today 3, 55-69.
65. Wu, G., and S. Yan, 2006a: Mutation trend of hemagglutinin of influenza A virus: a review from computational mutation viewpoint. Acta Pharmacol. Sin. 27, 513-526.
66. Wu, G., and S. Yan, 2006b: Fate of influenza A virus proteins. Protein Pept. Lett. 13, 377-384.
67. Wu, G., and S. Yan, 2008a: Lecture Notes on Computational Mutation. Nova Science Publishers, New York.
68. Wu, G., and S. Yan, 2008b: Prediction of mutations engineered by randomness in H5N1 neuraminidases from influenza A virus. Amino Acids 34, 81-90.
69. Wu, G., and S. Yan, 2008c: Prediction of mutation in H3N2 hemagglutinins of influenza A virus from North America based on different datasets. Protein Pept. Lett. 15, 144-152.
70. Wu, G., and S. Yan, 2008d: Prediction of mutations initiated by internal power in H3N2 hemagglutinins of influenza A virus from North America. Int. J. Pept. Res. Ther. 14, 41-51.
71. Wu, G., and S. Yan, 2008e: Prediction of mutations engineered by randomness in H5N1 hemagglutinins of influenza A virus. Amino Acid 35, 365-373.
72. Wu, G., and S. Yan, 2008f: Three sampling strategies to predict mutations in H5N1 hemagglutinins from influenza A virus. Protein Pept. Lett. 15, 731-738.
73. Wu, G., M. Baraldo, and M. Furlanut, 1999: Inter-patient and intra-patient variations in the baseline tapping test in patients with Parkinson's disease. Acta Neurol. Belg. 99, 182-184.
74. Zhou, G. Q., and W. Z. Zhong, 1982: Diffusion-controlled reactions of enzymes. A comparison between Chou's model and Alberty-Hammes-Eigen's model. Eur. J. Biochem. 128, 383-387.